Global Biodefense Market is segmented By Product (Nuclear, Anthrax, Botulism, Smallpox, Others), By End User (Research Organizations, Hospitals, Others), By Region (North America, South America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Biodefense Market Overview
The Global Biodefense Market is estimated to reach at a CAGR of 5.7% during the forecast period 2024-2031
Biodefense constitutes medical measures to protect individuals against bioterrorism, including interventions such as drugs and vaccinations and research and public health preparations to defend against such biological attacks.
Biodefense Market Summary
|
Metrics |
Details |
|
Market CAGR |
5.7% |
|
Segments Covered |
By Product, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Download Sample
Biodefense Market Trends
The anthrax outbreak and the increasing focus on public health services for the development of tests and procedures to identify biothreat agents will drive the biodefense market in the forecast period.
The outbreak of anthrax will drive the biodefense market
A serious infectious disease caused by gram-positive is anthrax. They are rod-shaped bacteria known as Bacillus anthracis. A rare disease, human anthrax is most common in Africa and central and southern Asia. It also occurs more regularly in Southern Europe than elsewhere on the continent and is uncommon in Northern Europe and North America. Globally, at least 2,000 cases occur a year, with about two cases a year in the United States.
Control of anthrax among humans depends on the integration of veterinary and human health surveillance and control programs. Routine cross-notification between the veterinary and human health surveillance systems and close collaboration between the two health sectors is particularly important during epidemiological and outbreak investigations. Despite its horrifying potential as a biological weapon, anthrax has been a regularly occurring natural disease worldwide. It was a devastating disease during the early days of microbiology to the farming economy and domestic animals.
Increasing focus on public health services for the development of tests and procedures to identify biothreat agents will drive the biodefense market in the forecast period
Public health laboratories focus on diseases and the health status of population groups. They perform limited diagnostic testing, reference testing, and disease surveillance. They also provide emergency response support, perform applied research, and provide training for laboratory personnel.
The CDC Public Health Emergency Preparedness Cooperative Agreement provides funds to States to increase their response capabilities and public health preparedness. States must meet some requirements to decrease the time needed to detect, report biological threats to public health to improve public health laboratory preparedness. The public health agencies responsibilities are surveillance of infectious diseases, investigation and detection of outbreaks, identification of etiologic agents and their modes of transmission, and the development of control and prevention strategies.
The measures needed to prevent, control emerging infections are similar to those needed to check the threat of bioterrorism. Fundamental components of adequate public health infrastructure are maintaining effective disease surveillance and communication systems. Prerequisites to effective surveillance systems are ensuring adequate epidemiologic and laboratory capacity. Ensuring an adequate supply of drugs, laboratory reagents, antitoxins and vaccines are essential. Hence, it will drive the biodefense market in the forecast period.
Lack of awareness will hamper the biodefense market
The deliberate release of bacteria, viruses, or other germs to cause illness or death is called bioterrorism attack. They are often found in nature and can sometimes be made more harmful by increasing their ability to cause disease, spread, or resist medical treatment. While the biotechnology revolution presents opportunities for scientific breakthroughs, these technologies could help create biological weapons with catastrophic impacts in the wrong hands.
To reduce the threats of bioterrorism or biological warfare, there is a need for more intensive international cooperation for threat assessment, planning and enhancing society's awareness. It is important to limit this type of knowledge to organizations/states that have an interest in acquiring an arsenal of weapons and biological warfare agents. Hence, a lack of awareness will hamper the Biodefense Market.
COVID-19 Impact on Biodefense Market
A realization has been prompt by COVID-19 amongst the most powerful countries with ambitions of economic and military domination that in this age of unprecedented connectivity, any use of biological weapons would not only cause enormous self-harm to the originating country but would backfire on it. Hence, COVID-19 will drive the Biodefense Market.
Biodefense Market Segmentation Analysis
The nuclear products segment will dominate the market
The rising focus of the public agencies on mitigating the risks associated with the chemical, biological, radiological, and nuclear threats and increasing funding for biodefense will dominate this segment of the market. Bioterrorism and biowarfare have been used for centuries to terrorize, weaken, incapacitate and defeat armies and whole populations of people. Historically, the pathogens used were naturally occurring, such as the plague and smallpox. However, with new genetic manipulation technologies and bacterial and viral culturing capabilities, it is possible to engineer organisms resistant to common antibiotics and antivirals for conducting bioterrorism attacks.
FDA approved a treatment on January 28, 2021 which will increase survival in pediatric patients (including term neonates) and adults acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]).
Research organizations will dominate the biodefense market
Biodefense research NIAID runs the entire spectrum from basic research to develop new drugs, vaccines and diagnostics. The research program includes preclinical development, target identification, and clinical evaluation of experimental products. Research resources such as genomics information and new laboratories are also essential. The Institute's initiatives involve NIAID scientists, industry, and academia.
Research also focuses on host responses to these organisms and toxins. To develop safe,potent,effective vaccines, accurate diagnostics, and immunotherapeutics, it is critical to improve our understanding of the complex parameters of innate and adaptive immunity. Because most potential bioterror agents would infect via the respiratory or oral routes, emphasis is also placed on studies of mucosal immunity at these sites.
On June 10, 2021, The FDA has approved a new drug to treat smallpox. Fearful of a possible bioweapon attack, the United States has been steadily preparing a defense through Biomedical Advanced Research and Development Authority (BARDA).
Global Biodefense Market Geographical Share
North America region will dominate the biodefense market
The increased government funding for sufficient vaccines and various R&D initiatives will dominate the market in this region. United States government spending on biodefense programs has enormously increased. Biodefense of U.S was once exclusively the domain of military agencies and was aimed principally at protecting battlefield troops against the products of state-run biological warfare programs. As the U.S. government begins preparing its Global HealthSecurity Strategy and finalizes its new National Biodefense Strategy, understand the current policy landscape and the potential ability or inability of policies to achieve biodefense objectives is crucial to ensure that the new strategies address long-standing gaps.
Despite all of this activity in biodefense and biosecurity policy, systematic evaluation of existing policy, and implementation to identify gaps and policy solutions for addressing those gaps has not been conducted, until now. The U.S. biosecurity and biodefense policy landscape is a system of intersecting components, leading to mutually reinforcing policies or counteracting policies. Therefore, approaching U.S. policy development, analysis, and implementation in a systematic way enables a more thorough understanding of the indirect costs, trade-offs, and feasibility of policies and their implementation.
CBER plays an integral role in the U.S. Government’s efforts to reduce bioterrorism and comprises a number of essential elements. One such element is the development and licensing of products to diagnose, treat or prevent disease following exposure to pathogens which have been identified as bioterrorist agents.
Biodefense Market Players and Competitive Landscape
Major key players Achaogen Inc., Alnylam Pharmaceuticals Inc., Altimune Inc. (PharmAthene Inc.), Bavarian Nordic A/S, Cleveland BioLabs Inc., Dynavax Technologies Corporation, Dynport Vaccine Company LLC (General Dynamics Corporation), Elusys Therapeutics Inc., Emergent Biosolutions Inc., Ichor Medical Systems Inc., Ology Bioservices Inc., SIGA Technologies, Inc., Zhengzhou YKinspection Enterprise Co., Ltd., Chongqing Xishan Science & Technology Co., Ltd, Guangzhou Lety Medical Limited
Alnylam Pharmaceuticals Inc.
Overview: Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. They are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio-metabolic, acute hepatic infectious, and central nervous system (CNS) and ocular diseases.
It was found in 2002 based on a Nobel Prize-winning breakthrough in biology, the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. The company is relentless in their pursuit of new treatments because they believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, they believe that patients shouldn’t have to wait for hope.
Product Portfolio: The company comprises Biotech, Pharmaceuticals, Biopharma, Drug Development, Rare Diseases, and RNAi.
Key Development: The leading RNAi therapeutics company announced that the U.S. Food and Drug Administration (FDA) had accepted the company’s New Drug Application (NDA) for vutrisiran, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is an investigational RNAi therapeutic. The FDA set an action date of April 14, 2022, under the Prescription Drug User Fee Act (PDUFA).
The biodefense market report would provide an access to an approx. 53 market data table, 44 figures and 200 pages.
